Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells

• Published in: Pharmacological research Vol. 128; pp. 252 - 263
• Main Authors: Wojtala, Martyna, Macierzyńska-Piotrowska, Ewa, Rybaczek, Dorota, Pirola, Luciano, Balcerczyk, Aneta
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-02-2018; Elsevier
• Subjects: Azepines - pharmacology; Cell cycle; Cell Line; Cell Proliferation - drug effects; Cell Proliferation - physiology; Chk1; Endothelial Cells - drug effects; Endothelial Cells - physiology; Epigenetics; G9a histone methyltransferase; Histocompatibility Antigens - genetics; Histocompatibility Antigens - physiology; Histone-Lysine N-Methyltransferase - antagonists & inhibitors; Histone-Lysine N-Methyltransferase - genetics; Histone-Lysine N-Methyltransferase - physiology; Homeostasis; Humans; Life Sciences; Microvessels - cytology; Oxidation-Reduction; Quinazolines - pharmacology; RNA, Small Interfering - genetics; HMTs; CAT; TAC; Cell cycle; Epigenetics; SOD; H2DCFDA; Chk1; HMEC-1; ABTS; G9a histone methyltransferase
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2017.10.014

[Display omitted]
Epigenetic mechanisms, including histone post-translational modifications, are central regulators of cell cycle control. The euchromatic G9a histone methyltransferase (G9a HMT) is a key enzyme catalyzing histone H3 methylation on lysines 9 and 27, and its dysregulation has been linked to uncontrolled proliferation of tumor cells. Here, we have investigated the effect of G9a HMT silencing on cell proliferation of microvascular endothelial cells, a process necessary to sustain tumor growth through the formation of the vascular capillary network.
Inhibition of G9a HMT activity in human microvascular endothelial cells (HMEC-1) was performed either pharmacologically, by treatment of cells with BIX-01294 or chaetocin, or transcriptionally, using shRNA. Cell viability and proliferation were examined using the resazurin reduction assay, flow cytometry and immunostaining of phosphorylated checkpoint kinase 1 (pSer317Chk1). Expression of cell cycle- and redox homeostasis-related genes was determined by quantitative PCR. Reactive oxygen species production was measured by oxidation of the fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate and the cell’s total antioxidant capacity by using the ABTS assay.
Inhibition of G9a HMT activity by BIX-01294 treatment or by shRNA attenuated the proliferation of HMEC-1, nuclear localization of phosphorylated Chk1, and induced cell cycle arrest in G1 phase. Transcriptional analysis demonstrated increased gene expression of the cyclin-dependent kinase (CDK) inhibitor p21, and also of Rb1, in BIX-01294 treated cells. Decreased proliferation rate was accompanied by enhanced antioxidant potential of HMEC-1 cells, as demonstrated by reduced production of reactive oxygen species, increased total antioxidant capacity and expression of the antioxidant enzymes catalase and superoxide dismutase 1.
Collectively, our results demonstrate of the central role of G9a HMT in the promotion of endothelial cells proliferation, and suggest that endothelial G9a HMT may be a target in the treatment of vascular proliferative disorders and tumor neovascularization.